Trials / Completed
CompletedNCT00385645
Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis
Comparison of 2 Alternative Antiretroviral Combinations in HIV Post-exposure Prophylaxis: AZT-3TC (Combivir®) + Lopinavir-ritonavir (Kaletra®) Versus AZT-3TC (Combivir®)+ Atazanavir (Reyataz®). Multicentre, Prospective, Randomized, Open Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 255 (actual)
- Sponsor
- Hospital Clinic of Barcelona · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study compares the adherence of 240 HIV-negative subjects randomly assigned to 2 different antiretroviral therapies for 28 days after accidental exposure to HIV.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Combivir+Kaletra | |
| DRUG | Combivir+Reyataz |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2006-10-11
- Last updated
- 2010-03-31
Locations
7 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT00385645. Inclusion in this directory is not an endorsement.